AstraZeneca gets CDSCO approval to launch eculizumab in India

Share it

Eculizumab, a monoclonal antibody, is indicated for the treatment of two rare and life-threatening conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH), a blood disorder that destroys red blood cells and causes blood clots and organ damage, and Atypical Hemolytic Uremic Syndrome (aHUS), which leads to abnormal blood clotting, often resulting in kidney failure and other complications. The AstraZeneca stock ended marginally in the green on Thursday, January 16 at ₹6,750 apeice. 

Leave a Comment

Your email address will not be published. Required fields are marked *